文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

全基因组测序揭示结核分枝杆菌利奈唑胺耐药相关突变

Characterization of linezolid-resistance-associated mutations in Mycobacterium tuberculosis through WGS.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

研究对结核分枝杆菌H37Rv体外平行选择利奈唑胺耐药分离株,用全基因组测序鉴定耐药相关突变。181个初筛菌落中154个确认耐药,88.3%(136/154)携带rplC T460C(C154R),其余18株携带rrl单突变(G2814T占7.8%,G2270T占3.9%)。未发现新基因突变与利奈唑胺耐药相关,提示rrl和rplC应为分子检测主要靶标。

要点

  • 体外筛选的154株利奈唑胺耐药株中88.3%携带rplC T460C(C154R)。
  • 其余耐药株携带rrl单突变:G2814T占7.8%,G2270T占3.9%。
  • 全基因组分析未发现新的利奈唑胺耐药相关基因突变。

核心结论

  • 体外全基因组研究未发现新的利奈唑胺耐药相关基因突变。
  • rrl和rplC应作为利奈唑胺耐药分子检测的主要靶标。

研究设计与样本

  • 初筛平板上出现的181个菌落中154个经二次利奈唑胺平板生长确认耐药,并对其进行全基因组测序。

主要发现

  • 154株确认耐药株中88.3%(136/154)携带rplC T460C突变,导致C154R氨基酸 substitution。
  • 其余18株携带rrl基因单突变,G2814T占7.8%(12/154),G2270T占3.9%(6/154)。

关键数值与推荐

  • 利奈唑胺体外选择浓度为2.5 mg/L(7H11琼脂平板)。
  • 耐药确认标准为在第二块利奈唑胺平板上生长。

临床怎么用

  • 分子检测利奈唑胺耐药应优先靶向rrl和rplC基因。
  • rplC T460C和rrl G2814T、G2270T是体外筛选耐药株中的主要突变。

局限性

  • 结果为体外平行选择实验,未在临床分离株中验证。
  • 仅基于H37Rv菌株,未涵盖其他遗传背景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Linezolid is becoming an important antibiotic for treating MDR/XDR TB, but the mutations conferring resistance to linezolid remain inadequately characterized. Herein, we investigated the linezolid-resistance-associated mutations on a whole-genome scale through parallel selections of resistant isolates in vitro. METHODS: Ten parallel Mycobacterium tuberculosis H37Rv cultures were subjected to spontaneous mutant selection on 7H11 agar plates containing 2.5 mg/L linezolid. The linezolid resistance of resulting colonies was confirmed by growth on a second linezolid plate. WGS was then performed to identify mutations associated with linezolid resistance. RESULTS: Of 181 colonies appearing on the initial linezolid plates, 154 were confirmed to be linezolid resistant. WGS showed that 88.3% (136/154) of these isolates had a T460C mutation in rplC, resulting in a C154R substitution. The other 18 isolates harboured a single mutation in the rrl gene, with G2814T and G2270T mutations accounting for 7.8% (12/154) and 3.9% (6/154), respectively. CONCLUSIONS: No mutations in novel genes were associated with linezolid resistance in a whole-genome investigation of 154 linezolid-resistant isolates selected in vitro. These results emphasize that rrl and rplC genes should be the major targets for molecular detection of linezolid resistance.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Pi R, Liu Q, Jiang Q, et al. Characterization of linezolid-resistance-associated mutations in Mycobacterium tuberculosis through WGS. J Antimicrob Chemother. 2019. PMID: 31225608. doi:10.1093/jac/dkz150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。